mProX™ Human KCNQ4 Stable Cell Line

Product Information

Target Protein

KCNQ4

Target Family

Kv7

Target Protein Species

Human

Host Cell Type

CHO-K1; HEK293

Target Classification

Ion Channel Cell Lines

Target Research Area

Auditory and Otology Research; CNS Research

Related Diseases

Deafness; Autosomal Dominant 2A; Dfna2 Nonsyndromic Hearing Loss

Gene ID

9132

UniProt ID

P56696

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

Instructions for producing a protein that belongs to a family of potassium channels are provided by the KCNQ4 gene. Certain inner ear cells and a portion of the neuronal pathway leading from the ear to the brain have potassium channels that are produced using the KCNQ4 protein. The heart and a few other muscles also have KCNQ4 potassium channels, albeit to a smaller degree. Sound waves must be converted into electrical nerve signals in order for the brain to receive them and process them into hearing. Many procedures are involved in this conversion, one of which is keeping the potassium ion levels in the inner ear at the appropriate amounts. Maintaining these levels is made possible by KCNQ4 channels, which are essential for the effective transfer of electrical nerve signals from the inner ear to the brain. The customized KCNQ4 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Charles

I purchased the KCNQ4 cell line. Hope it will work well. Oct 08 2022

chat Verified Customer

chat Elizabeth

The KCNQ4 Stable Cell Line is great for cardiovascular research. Dec 21 2022

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 Effects of DFNA2 mutations on KCNQ4 subunit interaction

DFNA2 mutations' effects on KCNQ4 subunit interaction In HEK293T cells, each HA-tagged mutant KCNQ4 channel was co-expressed at a 1:1 ratio with the Myc-tagged WT KCNQ4. As positive and negative controls, the vector and the WT HA-KCNQ4 were likewise co-expressed with the WT Myc-KCNQ4 channel. 24 hours after the transfections, the cell lysates were extracted and utilized in the reciprocal co-immunoprecipitation experiment.

Ref: Gao, Yanhong, et al. "Impaired surface expression and conductance of the KCNQ 4 channel lead to sensorineural hearing loss." Journal of cellular and molecular medicine 17.7 (2013): 889-900.

Pubmed: 23750663

DOI: 10.1111/jcmm.12080

Research Highlights

Genetic abnormalities causing a decrease in KCNQ4 channel activity are the cause of nonsyndromic hearing loss, which is usually a late-onset, high-frequency loss that gradually gets worse.
Rim, John Hoon, et al. "Activation of KCNQ4 as a therapeutic strategy to treat hearing loss." International journal of molecular sciences 22.5 (2021): 2510.
Pubmed: 33801540 DOI: 10.3390/ijms22052510

According to these results, genetic screening for KCNQ4 variations is crucial for the prevention and treatment of non-severe hearing loss (NSHL) since it suggests that these variants may contribute more to late-onset NSHL than previously thought.
Jung, Jinsei, et al. "Rare KCNQ4 variants found in public databases underlie impaired channel activity that may contribute to hearing impairment." Experimental & molecular medicine 51.8 (2019): 1-12.
Pubmed: 31434872 DOI: 10.1038/s12276-019-0300-9